Zhang Tiantai, Huang Zhentai, Dai Ying, Chen Xiuping, Zhu Ping, Du Guanhua
National Centre for Drug Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
J Biotechnol. 2006 Oct 1;125(4):492-502. doi: 10.1016/j.jbiotec.2006.03.040. Epub 2006 Jun 2.
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) was identified as a major receptor for oxidized low-density lipoprotein (oxLDL) in endothelial cells. LOX-1 critically mediates the endothelial dysfunction and the progression of atherosclerosis by oxLDL stimulation. It might be an important target for vascular endothelium. In order to obtain human LOX-1 and identify its mimic ligand for facilitating the study of LOX-1 function, a recombinant plasmid pPIC9K-His-hLOX-1 was structured and expressed human LOX-1 in Pichia pastoris GS115. Western blot analysis ensured the expressed recombinant human LOX-1 protein and a receptor-ligand binding assay showed that it had high binding affinity with oxLDL. With this receptor protein, a competitive fluorescence polarization-based high throughput screening method was established in a 384-well microplate to isolate the mimic ligands of human LOX-1. The evaluating parameter Z' value of 0.72 for this method showed that fluorescence polarization-based high throughput screening assay was robust and the results had a high reliability. By the fluorescence polarization-based high throughput screening assay, a total of 20,316 chemicals were screened, and 2 chemicals were identified that they have a high affinity with human LOX-1. Competitive uptake DiI-oxLDL assay by human LOX-1 transfected CHO-K1 cells further confirmed that two chemicals block the uptake of DiI-oxLDL. And the preliminary results indicated that isolated mimic ligands may act as a function of antagonist. The discovery of human LOX-1 mimic ligand would benefit to further study the function of LOX-1 and identify a novel avenue for prevention and treatment atherosclerosis.
凝集素样氧化低密度脂蛋白受体-1(LOX-1)被确定为内皮细胞中氧化低密度脂蛋白(oxLDL)的主要受体。LOX-1通过oxLDL刺激关键地介导内皮功能障碍和动脉粥样硬化的进展。它可能是血管内皮的一个重要靶点。为了获得人LOX-1并鉴定其模拟配体以促进LOX-1功能的研究,构建了重组质粒pPIC9K-His-hLOX-1并在毕赤酵母GS115中表达人LOX-1。蛋白质免疫印迹分析证实了表达的重组人LOX-1蛋白,受体-配体结合试验表明它与oxLDL具有高结合亲和力。利用这种受体蛋白,在384孔微孔板中建立了基于竞争性荧光偏振的高通量筛选方法,以分离人LOX-1的模拟配体。该方法的评估参数Z'值为0.72,表明基于荧光偏振的高通量筛选测定是可靠的,结果具有高可靠性。通过基于荧光偏振的高通量筛选测定,共筛选了20316种化学物质,鉴定出2种与人类LOX-1具有高亲和力的化学物质。人LOX-1转染的CHO-K1细胞的竞争性摄取DiI-oxLDL试验进一步证实这两种化学物质可阻断DiI-oxLDL的摄取。初步结果表明,分离出的模拟配体可能具有拮抗剂的功能。人LOX-1模拟配体的发现将有助于进一步研究LOX-1的功能,并为动脉粥样硬化的预防和治疗开辟新途径。